- Home
- ANIX vs JLS Comparison
ANIX vs JLS Comparison
Compare ANIX & JLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- JLS
- Stock Information
- Founded
- ANIX 1982
- JLS 2009
- Country
- ANIX United States
- JLS United States
- Employees
- ANIX N/A
- JLS N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- JLS Investment Managers
- Sector
- ANIX Health Care
- JLS Finance
- Exchange
- ANIX Nasdaq
- JLS Nasdaq
- Market Cap
- ANIX 95.7M
- JLS 103.4M
- IPO Year
- ANIX 1987
- JLS N/A
- Fundamental
- Price
- ANIX $4.90
- JLS $18.77
- Analyst Decision
- ANIX Strong Buy
- JLS
- Analyst Count
- ANIX 3
- JLS 0
- Target Price
- ANIX $9.00
- JLS N/A
- AVG Volume (30 Days)
- ANIX 216.1K
- JLS 26.6K
- Earning Date
- ANIX 09-10-2025
- JLS 01-01-0001
- Dividend Yield
- ANIX N/A
- JLS 9.33%
- EPS Growth
- ANIX N/A
- JLS N/A
- EPS
- ANIX N/A
- JLS N/A
- Revenue
- ANIX N/A
- JLS N/A
- Revenue This Year
- ANIX N/A
- JLS N/A
- Revenue Next Year
- ANIX N/A
- JLS N/A
- P/E Ratio
- ANIX N/A
- JLS N/A
- Revenue Growth
- ANIX N/A
- JLS N/A
- 52 Week Low
- ANIX $2.07
- JLS $15.48
- 52 Week High
- ANIX $4.49
- JLS $17.97
- Technical
- Relative Strength Index (RSI)
- ANIX 81.97
- JLS 50.53
- Support Level
- ANIX $3.21
- JLS $18.47
- Resistance Level
- ANIX $3.44
- JLS $18.98
- Average True Range (ATR)
- ANIX 0.21
- JLS 0.29
- MACD
- ANIX 0.13
- JLS -0.01
- Stochastic Oscillator
- ANIX 99.48
- JLS 65.70
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. Its investment objective to generate high current income through opportunistic investments in securitized credit.